Tuesday, May 5, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
News

Motif Neurotech's DOT wins FDA IDE for first clinical trial in treatment-resistant depression

The FDA has approved Motif Neurotech's investigational device exemption to begin a first-in-patient clinical trial of DOT, a millimeter-scale epidurally implanted wirelessly powered brain stimulator that targets the prefrontal cortex. The Rice University spinout, backed by former Neuralink president Max Hodak among others, becomes one of the first companies to attempt an implantable depression therapy at the size and patient-acceptance profile that has eluded every prior DBS-for-depression programme.

Apr 27, 2026 · 3 min read

Market Moves

Bioelectronic medicine reaches commercial inflection across four companies in two weeks

Spark Biomedical's CEO appointment on May 4 caps a fortnight of substantive bioelectronic-medicine milestones: SetPoint Medical's first multiple sclerosis pilot enrolment on April 30, ResMed's $340 million acquisition of Noctrix Health on the same day, and Nervonik's $52.5 million Series B on April 27. Together the four data points map onto a single maturation arc — growth-stage capital, late-stage trial expansion, commercial scaling, incumbent acquisition — and signal that the category is moving past early-clinical research into the operational layer where all four of those events run in parallel.

May 5 · 4 min read

Market Moves

Former Harvard chemistry chair Charles Lieber leads state-funded Shenzhen BCI lab i-BRAIN

Reuters reported on April 30 that Charles Lieber, the former chair of Harvard's chemistry department convicted in December 2021 under the US China Initiative, has been appointed director of i-BRAIN, a newly established BCI institute at the Shenzhen Medical Academy of Research and Translation. The lab gives Lieber access to dedicated nanofabrication, advanced lithography, and primate research facilities at a scale unavailable to him at Harvard. The appointment lands the same week as Axoft's $55M Asian-led Series A — the capital and talent legs of the same bilateral BCI flow.

Apr 30 · 3 min read

Industry News

UChicago Medicine joins Precision Neuroscience's clinical research network with Layer 7 sensorimotor partnership

Precision Neuroscience and UChicago Medicine announced on April 30 the launch of a clinical research partnership focused on AI-driven sensorimotor function and neuroprosthetics. The collaboration uses Precision's Layer 7 Cortical Interface, the FDA 510(k)-cleared high-density microelectrode array, and is the second material Precision institutional move of 2026, following the company's January integration with Medtronic's StealthStation surgical navigation system.

Apr 30 · 3 min read

Market Moves

Axoft draws C.P. Group lead in $55M Series A as US BCI company runs first acute implant in Shanghai

Cambridge, Massachusetts implantable BCI company Axoft closed a $55M oversubscribed Series A on April 29, led by Thai conglomerate Charoen Pokphand's strategic arm C.P. Group Innovation with Chinese co-investors Hillhouse and Gaorong, alongside US participants Alumni Ventures and Stanford. The same announcement disclosed Axoft's first acute intraoperative test of its Fleuron polymer probe in a Shanghai patient — the first publicly confirmed clinical use of a US BCI material in China, with more Chinese trials planned this year.

Apr 29 · 4 min read

Market Moves

Neurable launches OEM licensing programme, opening its EEG-decoder stack to consumer hardware makers

Neurable announced on April 28 that it has formally opened its consumer-EEG technology to OEM licensing, allowing third-party hardware makers to integrate the company's brain-signal-processing stack into their own products. Named integration partners include HP Inc.'s HyperX, MeSpace, iMotions, and the United States Air Force Research Laboratory. The shift recasts Neurable from a hardware company building its own consumer products into a platform layer for the broader consumer-electronics stack.

Apr 28 · 3 min read

Market Moves

China issues guided pricing for invasive BCI procedures as provinces begin reimbursement roll-out

China's National Healthcare Security Administration has set government-guided prices of 6,000–6,600 yuan per invasive brain-computer interface implantation procedure, with Sichuan, Hubei and Zhejiang now attaching fee schedules at the provincial level — moving the country further ahead of the United States on the reimbursement layer that will decide whether BCIs scale as routine medicine.

Apr 23 · 3 min read